8-K: Current report

16:08 ET

EFFECT: Others

Jan 21 06:06 ET

424B3: Prospectus

Jan 17 16:44 ET

8-K: Company Presentation

Jan 13 08:47 ET

S-1/A: General form for registration of securities under the Securities Act of 1933 (Amendment)

Jan 10 16:06 ET

SCHEDULE 13G: Others

Jan 3 19:52 ET

10-K: FY2024 Annual Report

Dec 17, 2024 16:44 ET

8-K: Applied DNA Announces Fourth Quarter and Fiscal Year 2024 Financial Results, Announces Strategic Restructuring to Prioritize the Manufacture of Critical Starting Materials for Genetic Medicines

Dec 17, 2024 16:14 ET

DEF 14A: Definitive information statements

Dec 10, 2024 16:06 ET

DEFA14A: Others

Dec 10, 2024 16:05 ET

S-1: General form for registration of securities under the Securities Act of 1933

Nov 19, 2024 06:21 ET

SC 13G: Statement of acquisition of beneficial ownership by individuals-Anson Funds Management LP(9.9%),Anson Management GP LLC(9.9%), etc.

Nov 14, 2024 17:52 ET

PRE 14A: Preliminary proxy statements relating to merger or acquisition

Nov 14, 2024 17:03 ET

SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Bruce Grossman(Less than 1%)

Nov 13, 2024 16:20 ET

8-K: Current report

Nov 13, 2024 11:27 ET

8-K: Current report

Nov 7, 2024 16:38 ET

SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-AMH Equity LLC(0.0%),Leviticus Partners, L.P.(0.0%)

Nov 7, 2024 10:13 ET

D: Filing D

Nov 6, 2024 16:33 ET

424B5: Prospectus

Oct 31, 2024 06:11 ET

8-K: Applied DNA Announces Pricing of $6.5 Million Registered Direct Offering and Concurrent Private Placement

Oct 31, 2024 06:06 ET